Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$358,000Cash on Hand
0.6mo Cash Runway
Follow ONMD by emailGet an email when ONMD reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ONMD, unsubscribe in one click. Privacy
📣 What ONMD Says Is Next
by November · “Third quarter 2026 revenue results are preliminary and are subject to finalization and adjustment in connection with the preparation of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, which we expect to release by November 16, 2026.”
Company press release, Nov 6, 2026 · SEC filing
fourth quarter of 2026 · “Our anticipated revenue pace in the fourth quarter of 2026 is expected for two reasons: our data coming direct from our healthcare provider partners, and our building of our de-identification pipeline and delivery infrastructure to scale with demand.”
Company press release, Nov 6, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 16, 2026 ·
Financing Prospectus supplement attaching the Q3 2026 10-Q for OneMedNet, which shows cash and equivalents of $137 thousand at September 30, 2026, down from $585 thousand at December 31, 2025. The filing covers up to 1,150,000 primary and 2,815,256 secondary shares. Form 424B3 · SEC filing
Nov 16, 2026 ·
Financing Prospectus Supplement No. 3 attaches OneMedNet's Q3 2026 Form 10-Q, covering up to 1,168,054 shares of common stock. Cash and equivalents fell to $137 thousand at September 30, 2026, from $585 thousand at December 31, 2025, and the Bitcoin holding was reduced to zero. Form 424B3 · SEC filing
Nov 9, 2026 ·
Earnings OneMedNet reported approximately $18.76 million in year-to-date contracted bookings as of November 6, 2026, of which $1.388 million has been converted to revenue through September 30, 2026. The company also published a growth recap and issued fourth-quarter 2026 revenue guidance. Form 8-K · SEC filing · Press release
Nov 6, 2026 ·
Earnings OneMedNet preliminarily reported about $1 million revenue for the quarter ended September 30, 2026, up 242% from the prior quarter and 465% from a year earlier. It guided to $12 million to $14 million of fourth-quarter 2026 revenue, pending customer acceptance of delivered data. Form 8-K · SEC filing · Press release
Oct 14, 2026 ·
Listing OneMedNet regained compliance with the Nasdaq $1.00 minimum bid price rule. Closing bid was at least $1.00 for 10 consecutive business days from September 29, 2026 through October 12, 2026, and the matter is closed. Form 8-K · SEC filing
Sep 30, 2026 ·
Listing OneMedNet filed a prospectus supplement attaching an 8-K reporting a 1-for-10 reverse stock split effective 12:01 a.m. ET on September 29, 2026, to meet Nasdaq's minimum bid price rule. Shares outstanding fall from about 60,125,902 to about 6,012,591. Form 424B3 · SEC filing
Sep 30, 2026 ·
Listing OneMedNet is implementing a 1-for-10 reverse stock split effective 12:01 a.m. ET on September 29, 2026, to regain compliance with Nasdaq's minimum bid price rule. Shares outstanding will fall from about 60,125,902 to about 6,012,591. Form 424B3 · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
ONMD holds $358,000 in cash and short-term investments (as of Jun 30, 2026) and burns about $1.7M/quarter from operations,
an estimated runway of 0.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:63 · High
Cash runway 1 months +40
S-1 registration (Jul 2026) +8
Going-concern doubt in the latest 10-Q +15Therefore, these conditions raise substantial doubt about the Company’s ability to continue as a going concern.10-Q, Nov 2026
Share count 6,201,813 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full ONMD picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ONMD and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.